Heart failure is a growing burden and health concern, says SHA chief

heart failure health burden sha
Saudi Arabia

Heart failure is a growing burden and health concern, says SHA chief

AstraZeneca, in collaboration with the Saudi Heart Association (SHA), revealed a new approved indication by the Saudi Ministry of Health and the Food and Drug Authority for Dapagliflozin, expanding its usage to patients with heart failure, ensuring they can access the right treatment as needed. Saudi Arabia is the first country in the GCC to provide such approval for the new indication.

 

A webinar organized by AstraZeneca in partnership with Saudi Heart Association, led by Prof.Waleed AlHabeeb, Consultant Heart Failure Cardiologist and President of the Saudi Heart Association, Prof. Mark Petrie – Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK together with a wider group of experts. The key topic of discussion at the event was the global and local burden of heart failure, the challenges it poses to patients and developments in treatment options.

UAE adopts its largest legislative reform in its history via 40 new laws and changes

Goldman Sachs thinks these 6 global stocks could rally by 60% or more

Goldman Sachs says these 6 energy stocks still have plenty of room to run

Sheikh Mohammed approves housing projects worth Dhs3.8 billion in Dubai